- Home
- MNPR vs OABI Comparison
MNPR vs OABI Comparison
Compare MNPR & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- OABI
- Stock Information
- Founded
- MNPR 2014
- OABI 2012
- Country
- MNPR United States
- OABI United States
- Employees
- MNPR N/A
- OABI N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- OABI Health Care
- Exchange
- MNPR Nasdaq
- OABI Nasdaq
- Market Cap
- MNPR 248.8M
- OABI 240.5M
- IPO Year
- MNPR 2019
- OABI N/A
- Fundamental
- Price
- MNPR $35.71
- OABI $2.01
- Analyst Decision
- MNPR Strong Buy
- OABI Strong Buy
- Analyst Count
- MNPR 7
- OABI 3
- Target Price
- MNPR $62.00
- OABI $6.67
- AVG Volume (30 Days)
- MNPR 20.7K
- OABI 480.3K
- Earning Date
- MNPR 08-12-2025
- OABI 08-06-2025
- Dividend Yield
- MNPR N/A
- OABI N/A
- EPS Growth
- MNPR N/A
- OABI N/A
- EPS
- MNPR N/A
- OABI N/A
- Revenue
- MNPR N/A
- OABI $23,027,000.00
- Revenue This Year
- MNPR N/A
- OABI N/A
- Revenue Next Year
- MNPR N/A
- OABI $45.02
- P/E Ratio
- MNPR N/A
- OABI N/A
- Revenue Growth
- MNPR N/A
- OABI 6.05
- 52 Week Low
- MNPR $2.15
- OABI $1.22
- 52 Week High
- MNPR $54.30
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- MNPR 43.81
- OABI 54.14
- Support Level
- MNPR $30.51
- OABI $1.69
- Resistance Level
- MNPR $36.51
- OABI $2.09
- Average True Range (ATR)
- MNPR 3.33
- OABI 0.11
- MACD
- MNPR -0.95
- OABI -0.01
- Stochastic Oscillator
- MNPR 37.55
- OABI 80.25
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.